多巴胺能药物对早期帕金森病患者睡眠障碍发生的影响  

Effects of Dopaminergic Agents on the Sleep Disorders of Parkinson Disease Patients at Early Stage

作　　者：高娟[1] 杨雪琴[1] 刘顺达[1] 张华[1] 曲传勇[1] 高永英[1] 齐明山[1] 

机构地区：[1]宁夏回族自治区人民医院神经内科,宁夏银川750021

出　　处：《现代生物医学进展》2014年第22期4308-4311,共4页Progress in Modern Biomedicine

基　　金：宁夏回族自治区重点科研计划课题(2012079)

摘　　要：目的:探讨多巴胺能药物及其它因素与早期帕金森病患者睡眠障碍之间的关系。方法:选择84名早期帕金森病患者作为病例组,87名健康人作为对照组。采用帕金森病睡眠量表(PDSS)评价患者的睡眠状况。采用非条件Logistic回归分析早期帕金森病患者睡眠障碍的影响因素。结果:早期帕金森病组PDSS总评分显著低于对照组(P=0.000);HAMD评分则显著高于对照组(P=0.000)。早期帕金森病患者睡眠障碍的主要类型为失眠。使用多巴胺能药物(OR=5.50,95%CI:1.96-15.81)是早期帕金森病患者发生睡眠障碍的危险因素;而较低的HAMD评分(OR=0.35,95%CI:0.13-0.93)则显著降低其睡眠障碍风险。结论:早期帕金森病患者存在睡眠障碍,多巴胺能药物和抑郁可能促进和加重其睡眠障碍。Objective： To evaluate the relationship between dopaminergic agents and sleep disorders of Parkinson disease（PD）patients at early stage. Methods： Eighty-four consecutive PD patients at early stage（Hoehn-Yahr grade Ⅰ- Ⅱ） and age-matched 87 healthy controls were enrolled in this study. Parkinson disease sleep scale（PDSS） was used to evaluate sleep status. Non-conditional Logistic regression models were used to calculate odds ratios and its corresponding 95% confidence interval（95%CI）. Results： The PDSS score of PD group was significantly lower than that of control group（P=0.000）, but the score of Hamilton depression rating scale（HAMD） of PD group was significantly higher than that of control group（P=0.000）. Agrypnia was found the main type of sleep disorder for PD patients at early stage. Dopaminergic agents（OR=5.50, 95%CI： 1.96-15.81） could increase risk of sleep disturbance, and lower score of HAMD（OR=0.35, 95%CI： 0.13-0.93） could decrease risk of sleep disorders among PD patients. Conclusion： Different types of sleep disorder could be found in PD patients at early stage. Dopaminergic agents and depression may make the situation of sleep disorders worse for PD patients at early stage. Intervention and treatment measures should be introduced to prevent development of sleep disorders among PD patients at early stage.

关 键 词：帕金森病 睡眠障碍 多巴胺能药物 抑郁 

分 类 号：R742.5[医药卫生—神经病学与精神病学]